In Vitro and In Vivo Crosstalk between Type I IFN and IL-8 Responses in SARS-CoV-2 Infection
Abstract
:1. Introduction
2. Materials and Methods
2.1. Plasma Samples
2.2. Virus Stock Preparation
2.3. In Vitro Infection of Vero E6 Cells
2.4. PBMC Infection
2.5. Viral RNA Amplification
2.6. IFN and Cytokine Detection
2.7. Statistical Analysis
2.8. Ethical Statement
3. Results
3.1. In Vitro Experiments for Viral Replication
3.2. IFN Induction and IL-8 Levels in PBMC Infected with SARS-CoV-2
3.3. IFN-α and IL-8 Levels in Plasma Samples from COVID-19 Patients
4. Discussion
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- World Health Organization. Available online: https://covid19.who.int/ (accessed on 16 March 2023).
- Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [Google Scholar] [CrossRef] [PubMed]
- Karki, R.; Kanneganti, T.-D. The ‘cytokine storm’: Molecular mechanisms and therapeutic prospects. Trends Immunol. 2021, 42, 681–705. [Google Scholar] [CrossRef] [PubMed]
- Zheng, Z.; Peng, F.; Xu, B.; Zhao, J.; Liu, H.; Peng, J.; Li, Q.; Jiang, C.; Zhou, Y.; Liu, S.; et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J. Infect. 2020, 81, e16–e25. [Google Scholar] [CrossRef] [PubMed]
- Karki, R.; Kanneganti, T.-D. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. J. Transl. Med. 2022, 20, 542. [Google Scholar] [CrossRef] [PubMed]
- Capobianchi, M.R.; Uleri, E.; Caglioti, C.; Dolei, A. Type I IFN family members: Similarity, differences and interaction. Cytokine Growth Factor Rev. 2015, 26, 103–111. [Google Scholar] [CrossRef]
- Gao, Y.; Li, T.; Han, M.; Li, X.; Wu, D.; Xu, Y.; Zhu, Y.; Liu, Y.; Wang, X.; Wang, L. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol. 2020, 92, 791–796. [Google Scholar] [CrossRef]
- Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J.; HLH Across Speciality Collaboration, UK. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020, 395, 1033–1034. [Google Scholar] [CrossRef]
- Manjili, R.H.; Zarei, M.; Habibi, M.; Manjili, M.H. COVID-19 as an Acute Inflammatory Disease. J. Immunol. 2020, 205, 12–19. [Google Scholar] [CrossRef]
- Kindler, E.; Thiel, V. SARS-CoV and IFN: Too Little, Too Late. Cell Host Microbe 2016, 19, 139–141. [Google Scholar] [CrossRef]
- Castilletti, C.; Bordi, L.; Lalle, E.; Rozera, G.; Poccia, F.; Agrati, C.; Abbate, I.; Capobianchi, M.R. Coordinate induction of IFN-α and -γ by SARS-CoV also in the absence of virus replication. Virology 2005, 341, 163–169. [Google Scholar] [CrossRef]
- Blanco-Melo, D.; Nilsson-Payant, B.E.; Liu, W.-C.; Uhl, S.; Hoagland, D.; Møller, R.; Jordan, T.X.; Oishi, K.; Panis, M.; Sachs, D.; et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 2020, 181, 1036–1045.e9. [Google Scholar] [CrossRef] [PubMed]
- Lucas, C.; Wong, P.; Klein, J.; Castro, T.B.R.; Silva, J.; Sundaram, M.; Ellingson, M.K.; Mao, T.; Oh, J.E.; Israelow, B.; et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020, 584, 463–469. [Google Scholar] [CrossRef]
- Galani, I.-E.; Rovina, N.; Lampropoulou, V.; Triantafyllia, V.; Manioudaki, M.; Pavlos, E.; Koukaki, E.; Fragkou, P.C.; Panou, V.; Rapti, V.; et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol. 2021, 22, 32–40. [Google Scholar] [CrossRef] [PubMed]
- Pasrija, R.; Naime, M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. Int. Immunopharmacol. 2021, 90, 107225. [Google Scholar] [CrossRef] [PubMed]
- Zhang, C.; Wu, Z.; Li, J.-W.; Zhao, H.; Wang, G.Q. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab may be the Key to Reduce Mortality. Int. J. Antimicrob. Agents 2020, 55, 105954. [Google Scholar] [CrossRef]
- Kuppalli, K.; Rasmussen, A.L. A glimpse into the eye of the COVID-19 cytokine storm. EBioMedicine 2020, 55, 102789. [Google Scholar] [CrossRef]
- Moore, B.J.B.; June, C.H. Cytokine release syndrome in severe COVID-19. Science 2020, 368, 473–474. [Google Scholar] [CrossRef]
- Zhong, J.; Tang, J.; Ye, C.; Dong, L. The immunology of COVID-19: Is immune modulation an option for treatment? Lancet Rheumatol. 2020, 2, e428–e436. [Google Scholar] [CrossRef]
- Soy, M.; Keser, G.; Atagündüz, P.; Tabak, F.; Atagündüz, I.; Kayhan, S. Cytokine storm in COVID-19: Pathogenesis and overview of anti-inflammatory agents used in treatment. Clin. Rheumatol. 2020, 39, 2085–2094. [Google Scholar] [CrossRef]
- Li, L.; Li, J.; Gao, M.; Fan, H.; Wang, Y.; Xu, X.; Chen, C.; Liu, J.; Kim, J.; Aliyari, R.; et al. Interleukin-8 as a Biomarker for Disease Prognosis of Coronavirus Disease-2019 Patients. Front. Immunol. 2021, 8, 602395. [Google Scholar] [CrossRef]
- Aman, M.J.; Rudolf, G.; Goldschmitt, J.; Aulitzky, W.E.; Lam, C.; Huber, C.; Peschel, C. Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood 1993, 82, 2371–2378. [Google Scholar] [CrossRef] [PubMed]
- Choi, A.M.; Jacoby, D.B. Influenza virus A infection induces interleukin-8 gene expression in human airway epitheial cells. FEBS Lett. 1992, 309, 327–329. [Google Scholar] [CrossRef] [PubMed]
- Khabar, K.S.; Al-Zoghaibi, F.; Al-Ahdal, M.N.; Murayama, T.; Dhalla, M.; Mukaida, N.; Taha, M.; Al-Sedairy, S.T.; Siddiqui, Y.; Kessie, G.; et al. The α Chemokine, Interleukin 8, Inhibits the Antiviral Action of Interferon α. J. Exp. Med. 1997, 186, 1077–1085. [Google Scholar] [CrossRef] [PubMed]
- Reed, L.J.; Muench, H.A. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27, 493–497. [Google Scholar]
- Corman, V.M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D.K.W.; Bleicker, T.; Brünink, S.; Schneider, J.; Schmidt, M.L.; et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance 2020, 25, 2000045. [Google Scholar] [CrossRef]
- Biava, M.; Caglioti, C.; Bordi, L.; Castilletti, C.; Colavita, F.; Quartu, S.; Nicastri, E.; Lauria, F.N.; Petrosillo, N.; Lanini, S.; et al. Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient. PLOS Pathog. 2017, 13, e1006065. [Google Scholar] [CrossRef]
- Biava, M.; Caglioti, C.; Castilletti, C.; Bordi, L.; Carletti, F.; Colavita, F.; Quartu, S.; Nicastri, E.; Iannetta, M.; Vairo, F.; et al. Persistence of ZIKV-RNA in the cellular fraction of semen is accompanied by a surrogate-marker of viral replication. Diagnostic implications for sexual transmission. New Microbiol. 2018, 41, 30–33. [Google Scholar]
- Maeda, T.; Obata, R.; Do, D.R.; Kuno, T. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City. J. Med. Virol. 2021, 93, 463–471. [Google Scholar] [CrossRef]
- Laguna-Goya, R.; Utrero-Rico, A.; Talayero, P.; Lasa-Lazaro, M.; Ramirez-Fernandez, A.; Naranjo, L.; Segura-Tudela, A.; Cabrera-Marante, O.; de Frias, E.R.; Garcia-Garcia, R.; et al. IL-6–based mortality risk model for hospitalized patients with COVID-19. J. Allergy Clin. Immunol. 2020, 146, 799–807.e9. [Google Scholar] [CrossRef]
- Zhang, Q.; Bastard, P.; Liu, Z.; Le Pen, J.; Moncada-Velez, M.; Chen, J.; Ogishi, M.; Sabli, I.K.D.; Hodeib, S.; Korol, C.; et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020, 370, eabd4570. [Google Scholar] [CrossRef]
- Yang, L.; Wang, J.; Hui, P.; Yarovinsky, T.O.; Badeti, S.; Pham, K.; Liu, C. Potential role of IFN-α in COVID-19 patients and its underlying treatment options. Appl. Microbiol. Biotechnol. 2021, 105, 4005–4015. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Biava, M.; Notari, S.; Grassi, G.; Bordi, L.; Tartaglia, E.; Agrati, C.; Cimini, E.; Sberna, G.; Nicastri, E.; Antinori, A.; et al. In Vitro and In Vivo Crosstalk between Type I IFN and IL-8 Responses in SARS-CoV-2 Infection. Microorganisms 2023, 11, 2787. https://doi.org/10.3390/microorganisms11112787
Biava M, Notari S, Grassi G, Bordi L, Tartaglia E, Agrati C, Cimini E, Sberna G, Nicastri E, Antinori A, et al. In Vitro and In Vivo Crosstalk between Type I IFN and IL-8 Responses in SARS-CoV-2 Infection. Microorganisms. 2023; 11(11):2787. https://doi.org/10.3390/microorganisms11112787
Chicago/Turabian StyleBiava, Mirella, Stefania Notari, Germana Grassi, Licia Bordi, Eleonora Tartaglia, Chiara Agrati, Eleonora Cimini, Giuseppe Sberna, Emanuele Nicastri, Andrea Antinori, and et al. 2023. "In Vitro and In Vivo Crosstalk between Type I IFN and IL-8 Responses in SARS-CoV-2 Infection" Microorganisms 11, no. 11: 2787. https://doi.org/10.3390/microorganisms11112787